Heparin in the treatment of severe sepsis: A new look at an old therapy

Critical Care Medicine

Volumn 36, Issue 11, 2008, Pages 3098-3099

  Dernaika, Tarek A ^a   Kinasewitz, Gary T ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Activated protein C; Anti inflammatory; Coagulation; Heparin; Sepsis

Indexed keywords

ANTITHROMBIN III; CELL ADHESION MOLECULE; CYTOKINE; DROTRECOGIN; HEPARIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; ANTICOAGULANT AGENT;

ANGIOGENESIS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BASOPHIL; BIOLOGICAL ACTIVITY; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG MEGADOSE; EDITORIAL; ENDOTHELIUM INJURY; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; LOW DRUG DOSE; MAST CELL; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SURVIVAL; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOSIS PREVENTION; NOTE;

ANTICOAGULANTS; HEPARIN; HUMANS; SEPSIS;

EID: 56049114417     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31818bdbc6     Document Type: Editorial

References (18)

1. Aird WC: Sepsis and coagulation. Crit Care Clin 2005; 21:417-431
2. Levi M, van der Poll T: Recombinant human activated protein C: Current insights into its mechanism of action. Crit Care 2007; 11(suppl 5):S3
3. Cox M, Nelson D: Lehninger, Principles of Biochemistry. New York, NY: Freeman, 2004, p 1100
4. Tyrell DJ, Kilfeather S, Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16:198-204
5. Day JR, Landis RC, Taylor KM: Heparin is much more than just an anticoagulant. J Cardiothorac Vasc Anesth 2004; 18:93-100
6. Nelson RM, Cecconi O, Roberts WG, et al: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82:3253-3258
7. Heinzelmann M, Bosshart H: Heparin binds to lipopolysaccharide(LPS)- binding protein, facilitates the transfer of LPS to CD14, and enhances LPS-induced activation of peripheral blood monocytes. J Immunol 2005; 174: 2280-2287
8. Chamorro A, Cervera A, Castillo J, et al: Un-fractionated heparin is associated with a lower rise of serum ascular cell adhesion molecule-1 in acute ischemic stroke patients. Neurosci Lett 2002; 328:229-232
9. Rogers C, Welt FG, Karnovsky MJ, et al: Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996; 16:1312-1318
10. Meyer J, Cox CS, Herndon DN, et al: Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993; 21:84-89
11. Griffin MP, Gore DC, Zwischenberger JB, et al: Does heparin improve survival in experimental porcine gram-negative septic shock? Circ Shock 1990; 31:343-349
12. Bernard GR, Vincent JL, Latererre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
13. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose an-tithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878
14. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
15. Davidson BL, Geerts WH, Lensing AW: Low-dose heparin for severe sepsis. N Engl J Med 2002; 347:1036-1037
16. Marcel L, Mitchell L, Williams MD, et al: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176:483-490
17. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979
18. Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98:253-259